Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KTTA
stocks logo

KTTA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-3.800
-0.37%
Estimates Revision
Stock Price
Go Up
up Image
+46.80%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Pasithea Therapeutics Corp (KTTA.O) is -0.08, compared to its 5-year average forward P/E of -4.53. For a more detailed relative valuation and DCF analysis to assess Pasithea Therapeutics Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.53
Current PE
-0.08
Overvalued PE
5.81
Undervalued PE
-14.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.71
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.61
Undervalued EV/EBITDA
-8.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.61
Current PS
0.00
Overvalued PS
52.72
Undervalued PS
-31.49
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

KTTA News & Events

Events Timeline

(ET)
2025-11-28
09:21:31
Pasithea Therapeutics sets public offering price at 75 cents for 80 million shares
select
2025-11-25 (ET)
2025-11-25
07:03:51
Pasithea Therapeutics Receives $1 Million Grant from ALS Association
select
2025-11-24 (ET)
2025-11-24
07:13:41
Pasithea Therapeutics finishes cohort 7 in Phase 1 study of PAS-004
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Newsfilter
PinnedPasithea Therapeutics Closes $60M Public Offering of 80M Shares
  • Successful Financing: Pasithea Therapeutics has completed a public offering of 80 million shares at $0.75 per share, raising approximately $60 million, which enhances the company's financial strength to support future R&D and clinical trials.
  • Cash Runway Extension: This financing is expected to extend the company's cash runway through at least the first half of 2028, ensuring ongoing investment in new drug development and clinical trials, thereby enhancing market competitiveness.
  • Clear Investment Direction: The company plans to use the proceeds for general corporate purposes, including ongoing research, clinical trials, and acquiring companies that complement its technologies, aiming to accelerate technological development and market expansion.
  • Increased Market Confidence: The offering was led by several healthcare-focused investors, indicating strong market confidence in Pasithea's future development, which may attract more investor interest in its subsequent progress.
[object Object]
Preview
2.0
12-01Benzinga
Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Vision Marine Technologies Performance: Vision Marine Technologies Inc. shares rose 10.5% to $1.36 in pre-market trading after announcing strong financial results for the fiscal year ending August 31, 2025, and highlighting strategic expansion following the acquisition of Nautical Ventures, which generated $12.8 million in revenue.

  • Other Gainers in Pre-Market Trading: Several stocks saw significant gains in pre-market trading, including WEBUY Global Ltd. (+62.1%), Direct Digital Holdings, Inc. (+60.6%), and INVO Fertility, Inc. (+24.7%), with various companies announcing acquisitions or strategic plans.

  • Notable Losers in Pre-Market Trading: SMX (Security Matters) PLC experienced a sharp decline of 24.6% after a previous surge, while Springview Holdings Ltd. fell 20.7% following a reverse share split announcement.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like New Fortress Energy Inc. and Canadian Solar Inc. also reporting notable increases.

[object Object]
Preview
8.5
12-01NASDAQ.COM
Pasithea Announces $60 Million Offering to Support PAS-004 and Expand Pipeline

  • Stock Performance: Pasithea Therapeutics Corp. (KTTA) shares surged by up to 38% following the announcement of a $60 million public offering of 80 million shares at $0.75 each, with the offering expected to close around December 1, 2025.

  • Use of Proceeds: The net proceeds from the offering will extend Pasithea's cash runway through at least the first half of 2028, funding ongoing research, clinical trials, and other operational needs.

  • Lead Candidate Development: Pasithea's lead candidate, PAS-004, is a next-generation MEK inhibitor currently in Phase 1 trials for advanced cancer and neurofibromatosis type 1, aiming to provide new treatment options for these conditions.

  • Recent Funding: The company received a $1 million grant from the ALS Association to study PAS-004 in amyotrophic lateral sclerosis (ALS), indicating an expansion of its research into neurodegenerative disorders.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pasithea Therapeutics Corp (KTTA) stock price today?

The current price of KTTA is 1.16 USD — it has decreased -0.85 % in the last trading day.

arrow icon

What is Pasithea Therapeutics Corp (KTTA)'s business?

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

arrow icon

What is the price predicton of KTTA Stock?

Wall Street analysts forecast KTTA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KTTA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pasithea Therapeutics Corp (KTTA)'s revenue for the last quarter?

Pasithea Therapeutics Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Pasithea Therapeutics Corp (KTTA)'s earnings per share (EPS) for the last quarter?

Pasithea Therapeutics Corp. EPS for the last quarter amounts to -0.41 USD, decreased -85.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pasithea Therapeutics Corp (KTTA)'s fundamentals?

The market is revising No Change the revenue expectations for KTTA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 46.80%.
arrow icon

How many employees does Pasithea Therapeutics Corp (KTTA). have?

Pasithea Therapeutics Corp (KTTA) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Pasithea Therapeutics Corp (KTTA) market cap?

Today KTTA has the market capitalization of 25.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free